reviewsChallenges of phase 1 clinical trials evaluating immune checkpoint-targeted antibodies
Under an Elsevier user license
open archive
Key words
immune checkpoint inhibitors
immunostimulatory monoclonal antibodies
drug development
phase 1
toxicity
adaptive designs
Cited by (0)
Copyright © 2015 European Society for Medical Oncology. Published by Elsevier Ltd. All rights reserved.